Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
interleukin-2
Biotech
Synthekine hopes new IL-2 will be the high-alpha in a beta class
IL-2 medicines have shown the ability to kill tumors. Synthekine hopes to do this without the associated toxicities with a new IL-2 alpha/beta molecule.
Annalee Armstrong
Apr 10, 2024 9:50am
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Mar 28, 2024 8:08am
Mural wants to paint new picture in IL-2 after Alkermes spinout
Nov 15, 2023 8:56am
Coya deems dementia drug R&D plan 'premature,' switches focus
Jun 12, 2023 9:00am
Neoleukin lays off 70% of staff, hunts for strategic alternative
Mar 9, 2023 5:45am
AstraZeneca deals another blow to IL-12 by dumping gene therapy
Feb 9, 2023 8:15am